{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 212,
  "pageCount": 415,
  "prevPage": 211,
  "nextPage": 213,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.",
  "elementsJson": [
    "paragraph",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/212",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-212",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "callout",
      "text": "Simulation assumes 100% bioavailability - Proglycem (many published sources) and DCCR (not disclosed)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43d54639-085e-470c-bffd-3efeda60f4be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.53,
        "y": 0.26
      },
      "kind": "callout",
      "text": "Poster figure (manipulated, in our view) -> DCCR = low bioavailability",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f038412d-7a62-478b-9166-8170fde9bad0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Therefore, our PK modeling leads us to conclude that Vykat is inferior from a PK standpoint vs. regular diazoxide – diazoxide has such a long half life that an extended-release version actually worsens its bioavailability profile.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a8-030c048879e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Simulated Plasma Concentration Curves for Diazoxide",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fd781f3-cef0-414e-8e6e-5bd637da303c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.53,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Figure 1. Plasma concentration 0-120 hours in clinical study PK001",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0495545-67d1-4f41-8571-1938d5a08d1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Therefore, our PK modeling leads us to conclude that Vykat is inferior from a PK standpoint vs. regular diazoxide – diazoxide has such a long half life that an extended-release version actually worsens its bioavailability profile. We note that various endocrinologists we interviewed noted diazoxide’s long half life, questioning why Soleno’s extended-release tablet was necessary.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "789640a2-208a-4639-a933-3a5fba0adc67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital analysis and estimates",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ff14dc0-bf25-4d19-bf7f-8533df5c5ce5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "ef4a7671-082b-4136-bf6d-2438395c2357",
      "evidence": "The slide uses a clear and simple chart to present the data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "4977adc5-c01b-492f-a17c-0142c56ca1f1",
      "evidence": "The slide explicitly claims data manipulation ('Poster figure (manipulated, in our view)') to expose a contradiction in the company's clinical narrative.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}